A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1738-1749

  Khan, Husain Yar ^a   Zubair, Haseeb ^a   Ullah, Mohd Fahad ^a   Ahmad, Aamir ^b   Hadi, Sheikh Mumtaz ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Cancer chemoprevention; Copper; DNA breakage; Polyphenols; Prooxidant action; ROS

Indexed keywords

2, 9 DIMETHYL 1, 10 PHENANTHROLINE; APIGENIN; CERULOPLASMIN; COPPER ION; CURCUMIN; ELLAGIC ACID; GALLOCATECHIN; GENISTEIN; LUTEOLIN; PHORBOL 13 ACETATE 12 MYRISTATE; PICEATANNOL; POLYPHENOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL; STILBENE; TANNIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CELL DEATH; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COPPER BLOOD LEVEL; CYTOTOXICITY; DNA DAMAGE; DNA DEGRADATION; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DRUG BIOAVAILABILITY; DRUG MECHANISM; HUMAN; LEUKEMIA; LYMPHOCYTE; MOBILIZATION; NEOPLASM; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION REACTION; REVIEW; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; CHEMOPREVENTION; COPPER; HUMANS; NEOPLASMS; OXIDANTS; OXIDATIVE STRESS; POLYPHENOLS; REACTIVE OXYGEN SPECIES;

EID: 84879303495     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545560     Document Type: Review

References (153)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Doll R, Peto R. Avoidable risk of cancer in the United States. J Nat Cancer Inst 1981; 66: 1197-1265.
3. Manson M. Cancer prevention -the potential for diet to modulate molecular signaling. Trends Mol Med 2003; 9: 11-18.
4. Block G, Patterson B, Subar A; Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr Cancer 1992; 18: 1-29.
5. Pavia M, Pileggi C, Nobile CG, Angelillo IF. Association between fruit and vegetable consumption and oral cancer: a meta-analysis of observational studies. Am J Clin Nutr 2006; 83: 1126-34.
6. Steinmetz KA, Potter JD; Vegetables, fruit, and cancer prevention: A review. J Am Diet Assoc 1996; 96: 1027-39.
7. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: A global perspective. Pharmacol Ther 2003; 99: 1-13.
8. Benetou V, Orfanos P, Lagiou P, Trichopoulos D, Boffetta P, Trichopoulou A; Vegetables and fruits in relation to cancer risk: Evidence from the Greek EPIC cohort study. Cancer Epidemiol Biomarkers Prev 2008; 17: 387-392.
9. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. Int J Cancer 2008; 122: 2330-2336.
10. Wollenweber E. Occurrence of flavonoid aglycones in medicinal plants. Prog Clin Biol Res 1988; 280: 45-55.
11. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22727-22737.
12. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. Fruit and vegetable juices and Alzheimer's disease: the Kame project. Am J Med 2006; 119: 751-759.
13. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007; 120: 45145-8.
14. Ullah MF, Khan MW. Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pac J Cancer Prev 2008; 9: 187-195.
15. Watson WH, Cai J, Jones D. Diet and apoptosis. Annu Rev Nutr 2000; 20: 485-505.
16. Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000; 60: 3823-3831.
17. Yang C, Landau J, Huang M, Newmark H. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001; 21: 381-397.
18. Knekt P, Järvinen R, Seppänen R, Hellövaara M, Teppo L, Pukkala E, Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997; 146: 223-230.
19. Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: A prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999; 81: 1248-1256.
20. Arts IC, Jacobs DR Jr, Gross M, Harnack LJ, Folsom AR; Dietary catechins and cancer incidence among postmenopausal women: The Iowa Women's Health Study (United States). Cancer Causes Control 2002; 13: 373-382.
21. Su L, Arab L. Tea consumption and the reduced risk of colon cancer - results from a national prospective cohort study. Public Health Nutr 2002; 5: 419-425.
22. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998; 89: 254-261.
23. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000; 92: 154-160.
24. Kagawa TF, Geierstanger BH, Wang AHJ, Ho PS. Covalent modification of guanine bases in double-stranded DNA: the 1:2-AZDNAstructure of dc(CACACG) in the presence of CuCl2. J Biol Chem 1991; 266: 20175-20184.
25. Geierstanger BH, Kagawa TF, Chen SL, Quigley GJ, Ho PS. Basespecific binding of copper(II) to Z-DNA. The 1.3-A single crystal structure of d(m5CGUAm5CG) in the presence of CuCl2. J Biol Chem 1991; 266: 20185-20191.
26. Swain J, Gutteridge JMC. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995; 368: 513-515.
27. Brewer G. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Dis Today 2005; 10: 1103-1109.
28. Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer 2004; 11: 255-263.
29. Apelgot S, Coppey J, Fromentin A, Guille E, Poupon MF, Roussel A. Altered distribution of copper (64Cu) in tumor bearing mice and rats. Anticancer Res 1986; 6: 159-164.
30. Semczuk B, Pomykalski M. Serum copper level in patients with laryngeal carcinoma. Otolaryngial Pol 1973; 27: 17-23.
31. Tani P, Kokkola K. Serum iron, copper and iron binding capacity in bronchogenic pulmonary carcinoma. Scand J Res Dis 1972; 80: 121-128.
32. Yucel I, Arpaci F, Ozet A, et al. Serum copper and zinc and copper/ zinc ratio in patients with breast cancer. Biol Trace Elem Res 1994; 40: 31-37.
33. Chan A, Wong F, Arumanayagam M. Serum ultrafiltrable copper, total copper and ceruloplasmin concentrations in gynecological carcinoma. Ann Clin Biochem 1993; 30: 545-549.
34. Carpentieri U, Myers J, Thorpe L, Daeschner CW, Haggard ME. Copper, zinc and iron in normal and leukemic lymphocytes from children. Cancer Res 1986; 46: 981-984.
35. Gupta SK, Shukla VK, Vaidya MP, Roy SK, Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol 1991; 46: 178-181.
36. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res 1984; 44: 5390-5394.
37. Margalioth EJ, Schenker JG, Chevion M. Copper and zinc levels in normal and malignant tissues. Cancer 1983; 52: 868-872.
38. Kuo KW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res 2002; 89: 1-11.
39. Zuo XL, Chen JM, Zhou X, Li XZ, Mei GY. Levels of selenium, zinc, copper and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res 2006; 114: 41-54.
40. Hrgovcic M, Tessmer CF, Thomas FB, Ong PS, Gamble JF, Shullenberger CC. Serum copper observations in patients with malignant lymphoma. Cancer 1973; 32: 1512-1524.
41. Scanni A, Licciardello L, Trovato M, Tomirotii M, Biraghi M. Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori 1977; 63: 175-180.
42. Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents. J Cell Biochem Suppl 1997; 28-29: 1-20.
43. Mayne S, Lippman S. Cancer prevention; Chemopreventive agents. In Cancer: Principles and Practices of Oncology. 5th Ed. (DeVita & Hellman S and Rosenberg S Eds) Philadelphia PA: Lippencott- Raven Publishers 1997; pp. 585-599.
44. Lepley DM, Li B, Birt DF, Pelling JC. The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis 1996; 17: 2367-2375.
45. Agullo G, Gamet-Payrastre L, Manenti S, et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol-3- kinase and protein kinase C inhibiton. Biochem Pharmacol 1997; 53: 1649-1657.
46. Skaper SD, Fabris M, Ferrari V, Carbonare MD, Leon A. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. Free Radic Biol Med 1997; 22: 669-678.
47. Sergediene E, Jonsson K, Szymusiak H, Tyrakowska B, Rietjensz ICM, Cenas N. Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett 1999; 462: 392-396.
48. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate, and induction of cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881-1886.
49. Chang KL, Cheng HL, Huang LW, et al. Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett 2008; 276: 14-20.
50. Clement HV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signalling-dependent apoptosis in human tumor cells. Blood 1998; 92: 996-1002.
51. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 2007; 6: 3071-3079.
52. Hillman GG, Singh-Gupta V. Soy isoflavones sensitize cancer cells to radiotherapy. Free Radic Biol Med 2011; 51: 289-298.
53. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702-6711.
54. Santandreu FM, Valle A, Oliver J, Roca P. Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem 2011; 28: 219-228.
55. Hadi SM, Asad SF, Singh S, Ahmad A. A Putative mechanism for anticancer and apoptosis inducing properties of plant-derived polyphenolic compounds. IUBMB Life 2000; 50: 167-171.
56. Elbling L, Weiss RM, Teufelhofer O, et al. Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB J 2005; 19: 807-809.
57. Gali HU, Perchellet EM, Klish DS, Hohnson JM, Perchellet JP. Hydrolysable tannins: potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-Otetradecanoyl phorbol-13-acetate. Int J Cancer 1992; 51: 425-432.
58. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999; 254: 739-743.
59. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms. Int J Oncol 2003; 23: 17-28.
60. Radin NS. Designing anticancer drugs via the achilles heel: ceramide, allylic ketones, and mitochondria. Bioorg Med Chem 2003; 11: 2123-2142.
61. Michels G, Wätjen W, Niering P, et al. Pro-apoptotic effects of the flavonoid luteolin in rat H4IIE cells. Toxicology 2005; 206: 337-348.
62. Shen SC, Ko CH, Tseng SW, Tsai SH, Chen YC. Structurally related antitumor effects of flavanones in vitro and in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production. Toxicol Appl Pharmacol 2004; 197: 84-95.
63. Noda C, He J, Takano T, et al. Induction of apoptosis by epigallocatechin- 3-gallate in human lymphoblastoid B cells. Biochem Biophys Res Commun 2007; 362: 951-957.
64. Herbert V. Prooxidant effects of antioxidant vitamins. J Nutr 1996; 126: 1197-1200.
65. Ahmad MS, Fazal F, Rahman A, Hadi SM, Parish JH. Activities of flavonoids for the cleavage of DNA in the presence of Cu(II): correlation with the generation of active oxygen species. Carcinogenesis 1992; 13: 605-608.
66. Bhat R, Hadi SM. DNA breakage by tannic acid and Cu(II): sequence specificity of the reaction and involvement of active oxygen species. Mutat Res 1994; 313: 39-48.
67. Ahsan A, Hadi SM. Strand scission in DNA induced by curcumin in the presence of Cu(II). Cancer Lett 1998; 124: 23-30.
68. Ahmad A, Asad SF, Singh S, Hadi SM. DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett 2000; 154: 29-37.
69. Azam S, Malik A, Hadi SM. Prooxidant property of green tea polyphenols epicatechin and epicatechin-3-gallate: implications for anticancer properties. Toxicol In vitro 2004; 18: 555-561.
70. Ahmad A, Asad SF, Singh S, Hadi SM. Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett 2005; 159: 1-12.
71. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5878.
72. Tsang WP, Chau SPY, Kong SK, Fung KP, Kwok TT. Reactive oxygen species mediated doxorubicin induced p53-independent apoptosis. Life Sci 2003; 73: 2047-2058.
73. Turella P, Cerella C, Filomeni G, et al. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 2005; 65: 3751-3761.
74. Kim SY, Kim SJ, Kim BJ, et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 2006; 38: 535-545.
75. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987; 139: 3199-3206.
76. Rahman A, Shahabuddin A, Hadi SM, Parish JH. Complexes involving quercetin, DNA and Cu(II). Carcinogenesis 1990; 11: 2001-2003.
77. Ehrenfeld GM, Shipley JB, Heimbrook DC, et al. Copperdependent cleavage of DNA by bleomycin. Biochemistry 1987; 26: 931-942.
78. Lee LT, Huang YT, Hwang JJ, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 2002; 22: 1615-1627.
79. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest 2003; 21: 744-757.
80. Whitsett T, Carpenter M, Lamartinere C. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 2006; 5: 15-25.
81. Scarlatti F, Sala G, Ricci C, et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007; 253: 124-130.
82. Piwocka K, Zablocki K, Weickowski MR, Skierski J. A novel apoptosis like pathway, independent of mitochondria and caspases, induced by curcumin in human lymphoblastoid T (Jurkat) cells. Exp Cell Res 1999; 249: 299-307.
83. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-598.
84. Gossner G, Choi M, Tan L, et al. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol 2007; 105: 23-30.
85. Opipari A, Tan L, Boitano A, Sorenson D, Aurora A, Liu J. Resveratrol- induced autophagocytosis in ovarian cancer cells. Cancer Res 2004; 64: 696-703.
86. Aoki H, Takada Y, Sawaya R, Aggarwal B, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and ERK signaling pathways. Mol Pharmacol 2007; 72: 29-39.
87. Shingima N, Yokoyama T, Kondo T, Kondo S. Roles of Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumininduced autophagy. Autophagy 2007; 3: 635-637.
88. Yoshino M, Haneda M, Naruse M, et al. Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2'- deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol In Vitro 2004; 18: 783-788.
89. Heiss EH, Schilder YDC, Dirsch VM. Chronic treatment with resveratrol induces redox stress- and ATM-dependent senescence in p53-positive cancer cells. J Biol Chem 2007; 282: 26759-26766.
90. Hadi SM, Bhat SH, Azmi AS, Hanif S, Shamim U, Ullah MF. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol 2007; 17: 370-376.
91. Hadi SM, Ullah MF, Azmi AS, et al. Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer. Pharm Res 2010; 27: 979-988.
92. Khan HY, Zubair H, Ullah MF, Ahmad A, Hadi SM. Oral administration of copper to rats leads to increased lymphocyte cellular DNA degradation by dietary polyphenols: implications for a cancer preventive mechanism. Biometals 2011; 24: 1169-1178.
93. Wolfe JT, Ross D, Cohen GM. A role for metals and free radicals in the induction of apoptosis in thymocytes. FEBS Lett 1994; 352: 58-62.
94. Held KD, Sylvester FC, Hopcia KL, Biaglow JE. Role of Fenton chemistry thiol-induced toxicity and apoptosis. Radiat Res 1996; 145: 542-553.
95. Satoh K, Kodofuku T, Sakagami H. Copper, but not iron, enhances apoptosis inducing activity of antioxidants. Anticancer Res 1997; 17: 2487-2490.
96. Bryan SE. Metal ions in biological systems. New York: Marcel Dekker 1979.
97. Burkitt MJ, Milne L, Nicotera P, Orrenius S. 1, 10-Phenanthroline stimulates internucleosomal DNA fragmentation in isolated rat liver nuclei by promoting redox activity of endogenous copper ions. Biochem J 1996; 313: 163-169.
98. Ebadi M, Swanson S. The status of zinc, copper and metallothionein in cancer patients. Prog Clin Biol Res 1988; 259: 161-175.
99. Margalioth EJ, Udassin R, Cohen C, Maor J, Anteby SO, Schenker JG. Serum copper level in gynecologic malignancies. Am J Obstet Gynecol 1987; 157: 93-96.
100. Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selective human brain tumors. J Neurooncol 1993; 16: 109-115.
101. Ebara M, Fukuda H, Hatano R, et al. Relationship between copper, zinc and metalothionein in hepatocellular carcinoma and its surrounding liver parenchyma. J Hepatol 2000; 33: 415-422.
102. Pizzolo G, Savarin T, Molino AM, Ambrosette A, Todeschini G, Vettore L. The diagnostic value of serum copper levels and other hematochemical parameters in malignancies. Tumorigenesis 1978; 64: 55-61.
103. Khan NS, Hadi SM. Structural features of tannic acid important for DNA degradation in the presence of Cu(II). Mutagenesis 1998; 13: 271-274.
104. Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y, Yabu Y. Antioxidant, gallic acid, induces apoptosis in HL60RG cells. Biochem Biophys Res Commun 1994; 204: 898-904.
105. Azmi AS, Bhat SH, Hadi SM. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: Implications for anticancer properties. FEBS Lett 2005; 579: 3131-5.
106. Azmi AS, Bhat SH, Hanif S, Hadi SM. Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: Implications for a putative mechanism for anticancer properties. FEBS Lett 2006; 580: 533-538.
107. Cao G, Sofic E, Prior R. Antioxidant and prooxidant behaviour of flavonoids: structure-activity relationship. Free Radic Biol Med 1997; 22: 749-760.
108. Kozics K, Valovicova Z, Slamenova D. Structure of flavonoids influences the degree inhibition of Benzo(a)pyrene - induced DNA damage and micronuclei in HepG2 cells. Neoplasma 2011; 58: 516-524.
109. Rahman A, Fazal F, Greensill J, Ainley K, Parish JH, Hadi SM. Strand scission in DNA induced by dietary flavonoids: role of Cu(I) and oxygen free radicals and biological consequences of scission. Mol Cell Biochem 1992; 111: 3-9.
110. Malik A, Azam S, Hadi N, Hadi SM. DNA degradation by water extract of green tea in the presence of copper ions: implications for anticancer properties. Phytother Res 2003; 17: 358-363.
111. Zheng LF, Wei QY, Cai YJ, et al. DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu(II) ions: mechanism and structure-activity relationship. Free Radic Biol Med 2006; 41: 1807-1816.
112. Hanif S, Shamim U, Ullah MF, Azmi AS, Bhat SH, Hadi SM. The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. Toxicology 2008; 249: 19-25.
113. Bhat SH, Azmi AS, Hadi SM. Prooxidant DNA breakage induced by caffeic acid in human peripheral lymphocytes: involvement of endogenous copper and a putative mechanism for anticancer properties. Toxicol Appl Pharmacol 2007; 218: 249-255.
114. Shamim U, Hanif S, Ullah MF, Azmi AS, Bhat SH, Hadi SM. Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: Implications for an anticancer mechanism. Free Radic Res 2008; 42: 764-772.
115. Ullah MF, Shamim U, Hanif S, Azmi AS, Hadi SM. Cellular DNA breakage by soy isflavone genistein and its methylated structural analogue biochanin A. Mol Nutr Food Res 2009; 53: 1376-1385.
116. Ullah MF, Ahmad A, Zubair H, et al. Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol Nutr Food Res 2011; 55: 553-559.
117. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005; 7: R897-R908.
118. Ullah MF, Ahmad A, Khan HY, Zubair H, Sarkar FH, Hadi SM. The Prooxidant Action of Dietary Antioxidants Leading to Cellular DNA Breakage and Anticancer Effects: Implications for Chemotherapeutic Action Against Cancer. Cell Biochem Biophys 2011; DOI 10.1007/s12013-011-9303-4.
119. Shamim U, Hanif S, Albanyan A, et al. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol 2012; 227: 1493-1500.
120. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996; 56: 1194-1198.
121. Courtois Y, Fromageot P, Guschlbauer W. Protonated polynucleotide structures. 3. An optical rotatory dispersion study of the protonation of DNA. Eur J Biochem 1968; 6: 493-501.
122. Kahle K, Huemmer W, Kempf M, Scheppach W, Erk T, Richling E. Polyphenols are intensively metabolized in the human gastrointestinal tract after apple juice consumption. J Agric Food Chem 2007; 55: 10605-10614.
123. Boocock DJ, Patel KR, Faust GE, et al. Quantitation of transresveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 182-187.
124. Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387-398.
125. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382.
126. Adlercreutz CH, Markkanen H, Watanabe S. Plasma concentration of phyto-oestrogen in Japanese men. Lancet 1993; 342: 1209-1210.
127. Pisano M, Pagnan G, Dettori MA, et al. Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol Cancer 2010; 9: 137.
128. Padhye S, Yang H, Jamadar A, et al. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 2009; 26: 1874-1880.
129. Dandawate PR, Vyas A, Ahmad A, et al. Inclusion Complex of Novel Curcumin Analogue CDF and -Cyclodextrin (1:2) and Its Enhanced In Vivo Anticancer Activity Against Pancreatic Cancer. Pharm Res 2012; 29: 1775-1786.
130. Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009; 69: 1712-1716.
131. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009; 37: 223-230.
132. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010; 390: 61-69.
133. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010; 351: 19-29.
134. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010; 79: 330-338.
135. Si HY, Li DP, Wang TM, et al. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol 2010; 10: 2325-2331.
136. Shao J, Li X, Lu X, et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces 2009; 72: 40-47.
137. Sou K, Oyajobi B, Goins B, Phillips WT, Tsuchida E. Characterization and cytotoxicity of self-organized assemblies of curcumin and amphiphatic poly(ethylene glycol). J Biomed Nanotechnol 2009; 5: 202-208.
138. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009; 29: 3867-3875.
139. Amin AR, Wang D, Zhang H, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin- 3-gallate and luteolin: potential role of p53. J Biol Chem 2010; 285: 34557-34565.
140. Greenwald P. Cancer chemoprevention. Br Med J 2002; 324: 714-718.
141. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780.
142. Li Y, Trush MA. Reactive oxygen-dependent DNA damage resulting from the oxidation of phenolic compounds by a copper-redox cycle mechanism. Cancer Res 1994; 54: 1895s-1898s.
143. Decker EA. Phenolics: prooxidants or antioxidants? Nutr Rev 1997; 55: 396-407.
144. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2008; 35: 32-46.
145. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105-11109.
146. Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 2011; 67: 103-110.
147. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
148. Zheng LF, Wei QY, Cai YJ, et al. DNA damage induced by resveratrol and its synthetic analogs in the presence of Cu(II) ions: mechanism and structure-activity relationship. Free Radic Biol Med 2006; 41: 1807-1816.
149. Powis G, Baker A. Redox signaling and the control of cell growth and death. Adv Pharmacol 1997; 38: 329-359.
150. Pervaiz S, Clement MV. Tumor intracellular redox status and drug resistance - serendipity or a causal relationship? Curr Pharm Des 2004; 10: 1969-1977.
151. O'Dwyer PJ, Hamilton TC, LaCreta FP, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-256.
152. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 2009; 101: 1978-1985.
153. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypothesis 2000; 55: 29-35.